structure of 2-[4-(Pyrrolidin-3-yloxy)phenyl]ethylamine

2-[4-(Pyrrolidin-3-yloxy)phenyl]ethylamine

CAS No.: 1000507-30-1
M. Wt: 206.28
M. Fa: C12H18N2O
InChI Key: LDFQXSKZZJTLSH-UHFFFAOYSA-N

Names and Identifiers of 1000507-30-1

CAS Number

1000507-30-1

MDL Number

MFCD09924818

IUPAC Name

2-[4-(pyrrolidin-3-yloxy)phenyl]ethan-1-amine

InChI

InChI=1S/C12H18N2O/c13-7-5-10-1-3-11(4-2-10)15-12-6-8-14-9-12/h1-4,12,14H,5-9,13H2

InChIKey

LDFQXSKZZJTLSH-UHFFFAOYSA-N

Canonical SMILES

NCCC1=CC=C(OC2CCNC2)C=C1

UNSPSC Code

12352100

Physical and chemical properties of 1000507-30-1

H Bond Acceptors

3

H Bond Donors

2

LogP

0.813802642

Molecular Formula

C12H18N2O

Molecular Weight

206.28

Safety Information of 1000507-30-1

Pictograms

Signal Word

 Warning

Safety Data Sheet
Supports customized editing of SDS information and downloading in PDF documents.

Applications of 1000507-30-1

The applications of 2-[4-(Pyrrolidin-3-yloxy)phenyl]ethylamine span various fields:

  • Pharmaceutical Development: Potential use as an antidepressant or anxiolytic agent due to its interaction with neurotransmitter systems.
  • Research Tool: As a ligand in receptor studies, aiding in the understanding of receptor-ligand interactions.
  • Chemical Probe: In biochemical assays to explore the effects of neurotransmitter modulation.

Interaction Studies of 1000507-30-1

Interaction studies focus on how 2-[4-(Pyrrolidin-3-yloxy)phenyl]ethylamine interacts with specific receptors and enzymes:

  • Receptor Binding Assays: Evaluating binding affinity to serotonin and dopamine receptors could provide insight into its therapeutic potential.
  • Enzyme Inhibition Studies: Investigating whether it inhibits enzymes involved in neurotransmitter metabolism, such as monoamine oxidase, would clarify its role in modulating neurotransmitter levels.

These studies are crucial for determining the compound's efficacy and safety profile in potential therapeutic applications.

Biological Activity of 1000507-30-1

2-[4-(Pyrrolidin-3-yloxy)phenyl]ethylamine is hypothesized to exhibit significant biological activity due to its structural features. Compounds with similar structures often interact with neurotransmitter receptors, potentially acting as:

  • Serotonin Reuptake Inhibitors: Similar compounds are known to affect serotonin levels, which could position this compound as a candidate for antidepressant development.
  • Dopamine Agonists: The structure may allow for interaction with dopamine receptors, influencing mood and behavior.

Studies on related compounds indicate that modifications in the amine and ether functionalities can significantly alter their pharmacological profiles.